LT3065759T - Imunosupresiniai agentai ir jų panaudojimo terapija - Google Patents

Imunosupresiniai agentai ir jų panaudojimo terapija

Info

Publication number
LT3065759T
LT3065759T LTEP14793594.4T LT14793594T LT3065759T LT 3065759 T LT3065759 T LT 3065759T LT 14793594 T LT14793594 T LT 14793594T LT 3065759 T LT3065759 T LT 3065759T
Authority
LT
Lithuania
Prior art keywords
therapy
immunosuppressive agents
immunosuppressive
agents
Prior art date
Application number
LTEP14793594.4T
Other languages
English (en)
Inventor
Marit Otterlei
Original Assignee
Norwegian University Of Science And Technology (Ntnu)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norwegian University Of Science And Technology (Ntnu) filed Critical Norwegian University Of Science And Technology (Ntnu)
Publication of LT3065759T publication Critical patent/LT3065759T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LTEP14793594.4T 2013-11-06 2014-11-06 Imunosupresiniai agentai ir jų panaudojimo terapija LT3065759T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1319620.9A GB201319620D0 (en) 2013-11-06 2013-11-06 Immunosuppressive agents and their use in therapy
PCT/EP2014/073966 WO2015067712A1 (en) 2013-11-06 2014-11-06 Immunosuppressive agents and their use in therapy

Publications (1)

Publication Number Publication Date
LT3065759T true LT3065759T (lt) 2021-08-10

Family

ID=49767770

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14793594.4T LT3065759T (lt) 2013-11-06 2014-11-06 Imunosupresiniai agentai ir jų panaudojimo terapija

Country Status (11)

Country Link
US (2) US10517923B2 (lt)
EP (1) EP3065759B1 (lt)
DK (1) DK3065759T3 (lt)
ES (1) ES2869901T3 (lt)
GB (1) GB201319620D0 (lt)
HR (1) HRP20210792T1 (lt)
LT (1) LT3065759T (lt)
PL (1) PL3065759T3 (lt)
PT (1) PT3065759T (lt)
RS (1) RS62047B1 (lt)
WO (1) WO2015067712A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201507721D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Immunosuppressive agents and their use in therapy
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
EP3432908A4 (en) * 2016-03-21 2020-07-29 Rhode Island Council on Postsecondary Education PEPTIDES SENSITIVE TO PH
CA3051855A1 (en) * 2017-01-27 2018-08-02 Vanderbilt University Fused in sarcoma (fus) nuclear translocation inhibitors for preventing fibrosis
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2020138674A1 (ko) * 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
JP2023529693A (ja) * 2020-06-12 2023-07-11 ケアジェン カンパニー，リミテッド ペンタペプチドを有効成分として含む組成物
KR102570768B1 (ko) * 2020-06-12 2023-08-28 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 다한증 치료용 조성물
KR102456989B1 (ko) * 2020-06-12 2022-10-21 (주)케어젠 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도
KR102483938B1 (ko) * 2020-06-12 2023-01-04 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물
KR102469721B1 (ko) * 2020-06-12 2022-11-23 (주)케어젠 보툴리눔 톡신 유사 활성을 갖는 펩타이드 및 이의 용도
KR102463320B1 (ko) * 2020-06-12 2022-11-07 (주)케어젠 펜타펩타이드를 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물
US11741686B2 (en) 2020-12-01 2023-08-29 Raytheon Company System and method for processing facility image data

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5439807A (en) 1992-05-19 1995-08-08 Xoma Corporation Methods for the preparation of endotoxin-binding proteins
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
CN1478543A (zh) 1993-03-12 2004-03-03 杀菌/增强通透性蛋白质产物的治疗用途
CA2158058C (en) 1993-03-12 2000-08-01 Roger G. Ii Little Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EP0722333B1 (en) 1993-10-05 2004-06-16 XOMA Technology Ltd. Bpi-protein-products for depressed reticuloendothelial system function
WO1995019179A1 (en) 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
JPH09508359A (ja) 1994-01-14 1997-08-26 ゾーマ コーポレイション 抗グラム陽性細菌学的方法および物質
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5646114A (en) 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
EP0824547B1 (en) 1994-09-15 2003-12-10 XOMA Technology Ltd. Anti-fungal peptides
US5912228A (en) 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US6057291A (en) * 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
AU727085B2 (en) 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
US5686414A (en) 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5851802A (en) 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
NZ505070A (en) 1996-05-10 2005-01-28 Xoma Corp An in vitro method for inhibiting Neisseria meningitidis bacteria of serogroups A, B, C and W135 using BPI
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
EP0907372B1 (en) 1996-05-23 2003-03-12 XOMA Technology Ltd. Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
JP2002509527A (ja) 1996-11-01 2002-03-26 ゾーマ コーポレイション 嚢胞性線維症におけるｂｐｉタンパク質産物の治療用途
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
SE512161C2 (sv) 1998-06-30 2000-02-07 Sandvik Ab Hårdmetall och användning av denna vid olje- och gasutvinning
AU6163099A (en) 1998-09-25 2000-04-17 Xoma Technology Ltd. Antifungal and antibacterial peptide
MXPA01007031A (es) 1999-01-22 2004-08-12 Xoma Technology Ltd Metodo para tratar enfermedades acrdiacas cronicas.
US6153584A (en) 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US6355616B1 (en) 1999-06-25 2002-03-12 Xoma (Us) Technology Ltd. Derivative compounds derived from or based on bactericidal/permeability-increasing protein
AU4209900A (en) 1999-07-12 2001-01-30 Xoma Technology Ltd. Methods to identify inhibitors of f1/f0 atpase
AU4204800A (en) 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
AU4204200A (en) 1999-07-12 2001-01-30 Xoma Technology Ltd. Therapeutic uses of bpi protein products for inhibiting H+/K+ atpase activity
US6436660B1 (en) 1999-07-12 2002-08-20 Xoma Technology Ltd. Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyes
EP1289472A4 (en) * 2000-05-30 2004-09-08 Advanced Res & Tech Inst COMPOSITIONS AND METHODS FOR IDENTIFYING MODULATORS OF PTEN FUNCTION AND PI-3 KINASE MECHANISMS
US20030166528A1 (en) 2000-10-11 2003-09-04 Jong-Jye Lin Antifungal compound
WO2002055099A2 (en) 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
CA2441562C (en) 2001-03-28 2013-05-14 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7517857B2 (en) 2002-01-29 2009-04-14 Posco Immune-modulating peptide
US20070280950A1 (en) * 2004-01-19 2007-12-06 Medical And Biological Laboratories Co., Ltd. Inflammatory Cytokine Inhibitors
ES2600460T3 (es) * 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7579318B2 (en) * 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP2010509234A (ja) * 2006-11-02 2010-03-25 シアトル ジェネティックス， インコーポレイテッド 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2362782A1 (en) * 2008-11-17 2011-09-07 The Provost, Fellows, Foundation Scholars, and the other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth A vaccinia virus protein a46 peptide and use thereof
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
WO2011043740A1 (en) * 2009-10-09 2011-04-14 Kemijski Institut Peptides for inhibition of myd88-dependent signaling pathways
WO2011104309A1 (en) * 2010-02-24 2011-09-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compounds for the treatment of inflammation and neutropenia
CN103842362B (zh) * 2011-05-09 2017-05-24 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
EP2732032B1 (en) * 2011-07-12 2016-05-11 The University of British Columbia Neuroprotective peptides that inhibit interaction between palmitoyl acyl transferase zinc- finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk)
WO2013110005A1 (en) * 2012-01-18 2013-07-25 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
KR101497972B1 (ko) * 2012-03-21 2015-03-03 서울대학교산학협력단 Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제
GB201319621D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) * 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy

Also Published As

Publication number Publication date
EP3065759A1 (en) 2016-09-14
US10517923B2 (en) 2019-12-31
WO2015067712A1 (en) 2015-05-14
EP3065759B1 (en) 2021-03-31
GB201319620D0 (en) 2013-12-18
PT3065759T (pt) 2021-05-17
PL3065759T3 (pl) 2021-10-25
HRP20210792T1 (hr) 2021-08-20
RS62047B1 (sr) 2021-07-30
ES2869901T3 (es) 2021-10-26
US11246907B2 (en) 2022-02-15
US20160279193A1 (en) 2016-09-29
DK3065759T3 (da) 2021-05-17
US20200323953A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
RS62047B1 (sr) Imunosupresivni agensi i njihova upotreba u terapiji
HK1221474A1 (zh) 多粘菌素衍生物及其在與不同抗生素的組合療法中的用途
IL246221B (en) Endazoles and their uses
GB201319621D0 (en) Antimicrobial agents and their use in therapy
IL240248A0 (en) Met-binding substances and their uses
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
IL245597A0 (en) Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases
HK1222561A1 (zh) 用於腫瘤學的組合物和方法
GB2515865B (en) Use of galactooligosaccharides in therapy
GB201310921D0 (en) Peptide-resin conjugate and use thereof
GB201305940D0 (en) Methods and arrays for use in the same
EP2853591A4 (en) HEMATOMIC HEMAZONE CELL LINE HLCZ01 AND USES THEREOF
GB201507721D0 (en) Immunosuppressive agents and their use in therapy
GB201308753D0 (en) Compounds and their use in therapy
IL243091B (en) Compositions and methods for use in oncology
HK1209033A1 (zh) 奧地帕西在治療黏多醣症病中的應用
GB201319273D0 (en) Improvements in structural members and methods relating thereto
GB201322869D0 (en) Therapeutic agents and delivery with microspheres
GB201304038D0 (en) Treated cells and therapeutic uses
GB201308217D0 (en) Compounds and their use in therapy
IL244576A0 (en) Anti-vstm5 antibodies and their use for treatment and diagnosis
GB201312129D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312131D0 (en) Drug combination and its use in therapy
AU2013901916A0 (en) An Agent and Use Thereof in Therapy